William Blair Reiterates “Market Perform” Rating for Kezar Life Sciences (NASDAQ:KZR)

Kezar Life Sciences (NASDAQ:KZR)‘s stock had its “market perform” rating reiterated by research analysts at William Blair in a report issued on Wednesday,RTT News reports.

Separately, HC Wainwright reissued a “neutral” rating on shares of Kezar Life Sciences in a research note on Monday, October 14th.

Kezar Life Sciences Price Performance

Shares of KZR opened at $7.52 on Wednesday. The stock has a fifty day moving average price of $7.16 and a 200 day moving average price of $6.85. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.58 and a current ratio of 7.65. Kezar Life Sciences has a 12 month low of $5.20 and a 12 month high of $11.35.

Kezar Life Sciences (NASDAQ:KZR) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($2.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.20) by $0.40. As a group, sell-side analysts anticipate that Kezar Life Sciences will post -11.95 EPS for the current fiscal year.

Hedge Funds Weigh In On Kezar Life Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Ikarian Capital LLC lifted its position in Kezar Life Sciences by 1.8% in the 1st quarter. Ikarian Capital LLC now owns 868,992 shares of the company’s stock worth $783,000 after buying an additional 15,601 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Kezar Life Sciences by 1.0% in the first quarter. Vanguard Group Inc. now owns 3,094,224 shares of the company’s stock valued at $2,790,000 after purchasing an additional 30,740 shares during the last quarter. Mackenzie Financial Corp bought a new stake in shares of Kezar Life Sciences in the second quarter valued at approximately $35,000. Acadian Asset Management LLC grew its position in Kezar Life Sciences by 3.6% in the 2nd quarter. Acadian Asset Management LLC now owns 1,855,194 shares of the company’s stock worth $1,112,000 after purchasing an additional 64,356 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its stake in Kezar Life Sciences by 35.4% during the first quarter. BNP Paribas Financial Markets now owns 273,430 shares of the company’s stock valued at $247,000 after acquiring an additional 71,543 shares during the period. Institutional investors and hedge funds own 67.90% of the company’s stock.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.